Foamy gland carcinoma of the prostate in needle biopsy: Incidence, gleason grade, and comparative α-methylacyl-coa racemase vs. ERG expression

American Journal of Surgical Pathology

Volumn 37, Issue 11, 2013, Pages 1709-1714

  Warrick, Joshua I ^a,b   Humphrey, Peter A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

adenocarcinoma; ERG; foamy gland; immunohistochemistry; prostate

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ERG PROTEIN, HUMAN; ISOMERASE; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; COMPARATIVE STUDY; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR;

ADENOCARCINOMA; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886395539     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318293d85b     Document Type: Article

References (26)

1. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 1996;20:419-426.
2. Carswell BM, Woda BA, Wang X, et al. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy. Histopathology. 2006;48:668-673.
3. Wolters T, Van der Kwast TH, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34:35-43.
4. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587.
5. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology. 2005;47:587-596.
6. Kunju LP, Rubin MA, Chinnaiyan AM, et al. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003;120:737-745.
7. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27: 772-778.
8. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6:429-439.
9. Van Leenders GJLH, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24: 1128-1138.
10. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
11. Furusato B, Tan S-H, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
12. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12:590-598.
13. Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-A comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012;15:165-169.
14. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011;459:441-447.
15. Miettinen M, Wang Z-F, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35: 432-441.
16. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol. 2010;23:1325-1333.
17. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009;22:1176-1185.
18. Hudson J, Cao D, Vollmer R, et al. Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol. 2012;43:974-979.
19. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
20. Epstein JI. An update of the Gleason grading system. J Urol. 2010;183:433-440.
21. Epstein JI, Cubilla AL, Humphrey PA. Tumors of the Prostate Gland, Seminal Vesicles, Penis, and Scrotum. Washington, DC: American Registry of Pathology; 2011.
22. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35: 1062-1068.
23. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
24. Zhao J, Epstein JI. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Am J Surg Pathol. 2009;33:583-590.
25. Arista-Nasr J, Martinez-Benitez B, Camorlinga-Tagle N, et al. Foamy gland microcarcinoma in needle prostatic biopsy. Ann Diagn Pathol. 2008;12:349-355.
26. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with atypical glands suspicious for cancer. Am J Surg Pathol. 2011;35:608-614.